Prospective observational study in comorbid patients with
chronic lymphocytic leukemia receiving first-line bendamustine
with rituximab

J 2019

Prospective observational study in comorbid patients with chronic lymphocytic leukemia receiving first-line bendamustine with rituximab

ŠPAČEK, Martin, Petra OBRTLÍKOVÁ, Stanislava HROBKOVÁ, Eduard CMUNT, Josef KARBAN et. al.

Základní údaje

Originální název

Prospective observational study in comorbid patients with chronic lymphocytic leukemia receiving first-line bendamustine with rituximab

Autoři

ŠPAČEK, Martin (203 Česká republika, garant), Petra OBRTLÍKOVÁ (203 Česká republika), Stanislava HROBKOVÁ (703 Slovensko, domácí), Eduard CMUNT (203 Česká republika), Josef KARBAN (203 Česká republika), Jan MOLINSKÝ (203 Česká republika), Martin ŠIMKOVIČ (203 Česká republika), Heidi MOCIKOVÁ (203 Česká republika), Lekaa MOHAMMADOVÁ (203 Česká republika), Anna PANOVSKÁ (203 Česká republika, domácí), Jan NOVÁK (203 Česká republika), Marek TRNĚNÝ (203 Česká republika), Lukáš SMOLEJ (203 Česká republika) a Michael DOUBEK (203 Česká republika, domácí)

Vydání

Leukemia Research, OXFORD, PERGAMON-ELSEVIER SCIENCE LTD, 2019, 0145-2126

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.214

Kód RIV

RIV/00216224:14110/19:00108491

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1016/j.leukres.2019.02.002

UT WoS

000460898400004

Klíčová slova anglicky

CLL; Bendamustine; Rituximab; Comorbid patients; CIRS; First-line treatment

Štítky

14110212, podil, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 31. 3. 2020 22:16, Mgr. Pavla Foltynová, Ph.D.

Anotace

V originále

Chemoimmunotherapy with bendamustine and rituximab is an alternative treatment for elderly patients with CLL. The aim of this observational multicenter study was to prospectively assess efficacy and safety of bendamustine and rituximab in front-line therapy in patients with CLL and significant comorbidities in real hematological practice. Eighty-three consecutive patients with cumulative illness rating scale (CIRS) > 6 who received at least one cycle of BR as first-line treatment were included in the study. The median age was 71 years (range, 53-83), the median CIRS was 8 (range, 7-17), and 60.2% of patients had a creatinine clearance <= 70 mL/min. FISH analysis, available for 78 cases, showed a del(17p) in 11.5% and del(11q) in 20.5% of patients. Overall response rate was 88.0% with a complete response rate of 20.5%. With median follow-up time of 22 months, the estimated median progression free survival was 35.9 months. Progression free survival and overall survival rates at 2 years were 69.9% and 96.2%, respectively. Grade 3 or 4 neutropenia, thrombocytopenia, and anemia were documented in 40 (48.2%), 14 (16.9%), and 8 (9.6%) patients, respectively. Grade 3 or 4 infections occurred in 14.5% of patients. Chemoimmunotherapy with BR is an effective therapeutic option with manageable toxicity for the initial treatment of CLL patients with significant comorbidities. ClinicalTrials.gov Identifier: NCT02381899.

Návaznosti

NV15-30015A, projekt VaV

Název: Analýza klonální heterogenity chronické lymfocytární leukemie pomoci sekvenování nové generace genu pro B-buněčný receptor. Národní studie.

Citovat

ŠPAČEK, Martin, Petra OBRTLÍKOVÁ, Stanislava HROBKOVÁ, Eduard CMUNT, Josef KARBAN, Jan MOLINSKÝ, Martin ŠIMKOVIČ, Heidi MOCIKOVÁ, Lekaa MOHAMMADOVÁ, Anna PANOVSKÁ, Jan NOVÁK, Marek TRNĚNÝ, Lukáš SMOLEJ a Michael DOUBEK. Prospective observational study in comorbid patients with chronic lymphocytic leukemia receiving first-line bendamustine with rituximab. Leukemia Research. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD, 2019, roč. 79, APR 2019, s. 17-21. ISSN 0145-2126. Dostupné z: https://dx.doi.org/10.1016/j.leukres.2019.02.002.

@article{1545812,
   author = {Špaček, Martin and Obrtlíková, Petra and Hrobková, Stanislava and Cmunt, Eduard and Karban, Josef and Molinský, Jan and Šimkovič, Martin and Mociková, Heidi and Mohammadová, Lekaa and Panovská, Anna and Novák, Jan and Trněný, Marek and Smolej, Lukáš and Doubek, Michael},
   article_location = {OXFORD},
   article_number = {APR 2019},
   doi = {http://dx.doi.org/10.1016/j.leukres.2019.02.002},
   keywords = {CLL; Bendamustine; Rituximab; Comorbid patients; CIRS; First-line treatment},
   language = {eng},
   issn = {0145-2126},
   journal = {Leukemia Research},
   title = {Prospective observational study in comorbid patients with chronic lymphocytic leukemia receiving first-line bendamustine with rituximab},
   url = {http://dx.doi.org/10.1016/j.leukres.2019.02.002},
   volume = {79},
   year = {2019}
}

TY  - JOUR
ID  - 1545812
AU  - Špaček, Martin - Obrtlíková, Petra - Hrobková, Stanislava - Cmunt, Eduard - Karban, Josef - Molinský, Jan - Šimkovič, Martin - Mociková, Heidi - Mohammadová, Lekaa - Panovská, Anna - Novák, Jan - Trněný, Marek - Smolej, Lukáš - Doubek, Michael
PY  - 2019
TI  - Prospective observational study in comorbid patients with chronic lymphocytic leukemia receiving first-line bendamustine with rituximab
JF  - Leukemia Research
VL  - 79
IS  - APR 2019
SP  - 17-21
EP  - 17-21
PB  - PERGAMON-ELSEVIER SCIENCE LTD
SN  - 01452126
KW  - CLL
KW  - Bendamustine
KW  - Rituximab
KW  - Comorbid patients
KW  - CIRS
KW  - First-line treatment
UR  - http://dx.doi.org/10.1016/j.leukres.2019.02.002
L2  - http://dx.doi.org/10.1016/j.leukres.2019.02.002
N2  - Chemoimmunotherapy with bendamustine and rituximab is an alternative treatment for elderly patients with CLL. The aim of this observational multicenter study was to prospectively assess efficacy and safety of bendamustine and rituximab in front-line therapy in patients with CLL and significant comorbidities in real hematological practice. Eighty-three consecutive patients with cumulative illness rating scale (CIRS) > 6 who received at least one cycle of BR as first-line treatment were included in the study. The median age was 71 years (range, 53-83), the median CIRS was 8 (range, 7-17), and 60.2% of patients had a creatinine clearance <= 70 mL/min. FISH analysis, available for 78 cases, showed a del(17p) in 11.5% and del(11q) in 20.5% of patients. Overall response rate was 88.0% with a complete response rate of 20.5%. With median follow-up time of 22 months, the estimated median progression free survival was 35.9 months. Progression free survival and overall survival rates at 2 years were 69.9% and 96.2%, respectively. Grade 3 or 4 neutropenia, thrombocytopenia, and anemia were documented in 40 (48.2%), 14 (16.9%), and 8 (9.6%) patients, respectively. Grade 3 or 4 infections occurred in 14.5% of patients. Chemoimmunotherapy with BR is an effective therapeutic option with manageable toxicity for the initial treatment of CLL patients with significant comorbidities. ClinicalTrials.gov Identifier: NCT02381899.
ER  -

ŠPAČEK, Martin, Petra OBRTLÍKOVÁ, Stanislava HROBKOVÁ, Eduard CMUNT, Josef KARBAN, Jan MOLINSKÝ, Martin ŠIMKOVIČ, Heidi MOCIKOVÁ, Lekaa MOHAMMADOVÁ, Anna PANOVSKÁ, Jan NOVÁK, Marek TRNĚNÝ, Lukáš SMOLEJ a Michael DOUBEK. Prospective observational study in comorbid patients with chronic lymphocytic leukemia receiving first-line bendamustine with rituximab. \textit{Leukemia Research}. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD, 2019, roč.~79, APR 2019, s.~17-21. ISSN~0145-2126. Dostupné z: https://dx.doi.org/10.1016/j.leukres.2019.02.002.

Podrobný výpis o publikaci